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Dear Editor 
We read with interest the article entitled “Does disseminated nontuberculous mycobacterial disease 
cause false-positive Determine TB-LAM lateral flow assay results? A retrospective review” by Nel et 
al [1]. The authors present an important finding relevant to clinicians managing patients with 
advanced HIV. Although we agree that disseminated nontuberculous mycobacterial (NTM) disease 
needs to be considered in patients with positive Determine TB-LAM lateral flow assay (LF-LAM) 
results, we urge that the implications for clinical practice be considered in the context of what is 
known about the relative incidence of tuberculosis and NTM disease in high HIV burden settings. 
Disseminated NTM is almost exclusively observed in patients with extreme immunosuppression 
(median CD4 count consistently <50 cells/μL, often <10 cells/μL) [2], has always been uncommon in 
HIV-infected patients in Africa, and has become rarer in the era of combination antiretroviral 
therapy (ART).   
Disseminated NTM accounted for only 1.5% of ID consults, and 4% of annual mycobacterial disease 
diagnoses in the Author’s hospital, vastly outweighed by Mycobacterium tuberculosis (MTB).  Even in 
this reported case series, 12% of NTM isolates occurred in patients also culture positive for MTB [1]. 
In a recent study from Cape Town [3], only 1 of 410 (0.2%) unselected HIV-positive patients admitted 
to medical wards and who had a mycobacterial blood cultures taken had evidence of disseminated 
NTM, compared to 132/410 (32.2%) with Xpert or culture-confirmed MTB. This individual had NTM 
mycobacteraemia, was strongly positive on urine LF-LAM, but also positive on two urinary Xpert 
MTB/RIF tests, implying mixed MTB/NTM disease (Xpert being specific for MTB). Similarly, a study 
from Malawi using systematic blood and sputum culture to investigate 467 sputum smear-negative 
HIV-positive patients starting ART with WHO Stage 4 disease isolated NTM in 4 (0.9%), compared to 
MTB in 48 (10.2%), and non-typhoid salmonella species in 29 (6.2%) [4].  
Given current evidence, disseminated NTM accounts for a very small proportion of mycobacterial 
disease in LAM-positive HIV patients in Southern Africa, greatly outnumbered by MTB disease. 
Mixed MTB/NTM disease also needs to be considered. 
We suggest use of Xpert MTB/RIF on concentrated urine to distinguish NTM from MTB disease in 
patients with positive LF-LAM results who have the risk-profile for NTM disease, including CD4 <50 
cells/μL. Misdiagnosing MTB or mixed MTB/NTM as NTM disease has serious consequence for 
patients, with NTM treatment being inadequate for MTB, and requiring prolonged use of expensive 
treatment not covered by National TB Programmes.   
We, therefore, agree that disseminated NTM should be considered as a cause of positive LF-LAM, 
but only when MTB and mixed MTB/NTM disease have been rigorously excluded. In addition to 
urine and sputum Xpert MTB/RIF testing, urine, blood or bone marrow mycobacterial culture (if 
available) can provide supportive evidence for this decision. The relative non-specificity between 
MTB and NTM should not detract from the routine use of LF-LAM to diagnose TB in appropriately 
selected HIV-positive populations, nor the treatment of LF-LAM positive patients with standard TB 
drug regimens [5]. In resource-limited settings, treatment of HIV-positive patients with positive urine 
LF-LAM using standard MTB regimens with no further investigations has been shown to reduce 
mortality [6]. 
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